NCT05484622 2026-03-12Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant GliomaServierPhase 1 Active not recruiting60 enrolled
NCT06047379 2026-03-02Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisNeonc Technologies, Inc.Phase 1/2 Recruiting134 enrolled
NCT04479241 2025-06-05LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent GlioblastomaIstari Oncology, Inc.Phase 2 Completed25 enrolled 12 charts
NCT04913337 2024-10-02Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor MalignanciesNGM Biopharmaceuticals, IncPhase 1/2 Active not recruiting179 enrolled
NCT05366062 2022-05-13ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and PembrolizumabEpitopoietic Research CorporationPhase 2 Not yet recruiting28 enrolled
NCT05053880 2021-11-19A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma MultiformeAccendatech USA Inc.Phase 1/2 Unknown48 enrolled